173.820 articles found

<i>TMEM106B</i> analysis in diverse cohorts suggests no association with Parkinson’s disease risk

Chaparro-Solano HM, Kanagasingam S, Gan-Or Z, Senkevich K, the Global Parkinson’s Genetic Program (GP2).

· 2026-10-02

DOI: 10.64898/2026.09.28.26363833

Interaction Between Exercise Intensity and Sedentary Behavior on VO 2 max Change in Patients with De Novo Parkinson Disease: The Study in Parkinson Disease of Exercise (SPARX) Phase 2 Randomized Clinical Trial

Check source for author details

medRxiv · 2026-10-02

TMEM106B analysis in diverse cohorts suggests no association with Parkinson’s disease risk

Check source for author details

medRxiv · 2026-10-02

Automated eye-tracking for Parkinson's disease diagnosis: a proof-of-concept cascade classifier study.

Menke JM, Aslam S, Rieiro H, Waldorf R, Shill HA.

Clin Park Relat Disord · 2026-10-02

DOI: 10.1016/j.prdoa.2026.100509PMID: 42876454

Comprehensive genetic screening of the South African Parkinson's disease study collection using the NeuroBooster array.

Step K, Madula L, Kuznetsov N, Maasdorp E, Carr J, van Coller R, Möller M, Mata IF, Bardien S, Global Parkinson's Genetics Program (GP2).

Clin Park Relat Disord · 2026-10-02

DOI: 10.1016/j.prdoa.2026.100508PMID: 42890374

An &lt;i&gt;in silico&lt;/i&gt; cortico-basal ganglia-thalamic testbed for comparing visual and deep brain stimulation in Parkinson's disease.

Huang CH, Chen WS, Lai JR, Cho CH, Sung YT, Chang CT, Lin CW.

Front Comput Neurosci · 2026-10-02

DOI: 10.3389/fncom.2026.1950516PMID: 42890761

Digital mobility assessment using wearable devices in people with Parkinson's disease: a feasibility and implementation study in Ghana (TraPCAf) compared with a UK cohort.

Bicer M, Kirk C, Agoriwo M, Cham M, Akpalu A, Okubadejo N, Sarvestan J, Lumsdon J, Okkaoglu Y, Brittain K, McArdle R, Alcock L, Yarnall AJ, Fothergill-Misbah N, Walker R, Rochester L, Del Din S, TraPCAf.

Front Aging Neurosci · 2026-10-02

DOI: 10.3389/fnagi.2026.1899045PMID: 42890933

Founder mutations in movement disorders: global distribution, molecular mechanisms, and clinical consequences-a scoping review.

Gowda N, Harish S.

Neurogenetics · 2026-10-02

DOI: 10.1007/s10048-026-00946-8PMID: 42825921

Cryoprobe to current practice: neurosurgical legacies of Dr. Irving S. Cooper in movement disorders.

Fisher K, Tsirelman K, Baweja SS, Jain AK, Fekete R.

J Neurosurg · 2026-10-02

DOI: 10.3171/2026.4.jns26203PMID: 42826401

From patient cells to patient therapy: Twenty years of iPSC-based translation in neurodegenerative disease.

Cha Y, Kim KS.

Cell Rep Med · 2026-10-02

DOI: 10.1016/j.xcrm.2026.103104PMID: 42826718

Identification of a shared blood-brain transcriptomic signature in Parkinson's disease using bioinformatic and network pharmacology approaches.

Mohammad H, Singh A, Bansal D.

Neuroscience · 2026-10-02

DOI: 10.1016/j.neuroscience.2026.09.044PMID: 42826760

Estradiol attenuates cardiac apoptosis and modulates cardiovascular remodeling in ovariectomized female rats with 6-hydroxydopamine-induced parkinsonism.

de Campos BH, Borges FH, Ariza D, de Jager L, Reginato GS, Gonçalves AB, Martins Novais Padrão AI, Fonseca H, Pinge-Filho P, Crestani CC, Martins-Pinge MC.

Physiol Behav · 2026-10-02

DOI: 10.1016/j.physbeh.2026.115520PMID: 42826823